The impact of PD-L1 expression in patients with metastatic GEP-NETs

Journal of Cancer

Volumn 7, Issue 5, 2016, Pages 484-489

  Kim, Seung Tae ^a   Ha, Sang Yun ^a   Lee, Sujin ^a   Ahn, Soomin ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Kim, Kyoung Mee ^a   Park, Young Suk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Gastroenteropancreatic neuroendocrine tumor (GEP NET); Programmed death ligand 1 (PD L1); WHO classification

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; DUODENUM CANCER; FEMALE; FOREGUT; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 84971508170     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13711     Document Type: Article

References (32)

1. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013; 339: 286-291.
2. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-998.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-899.
4. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 454: 436-444.
5. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410: 1107-1111.
6. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012; 30: 677-706.
7. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903-907.
8. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-567.
9. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013; 73: 128-138.
10. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013; 49: 2233-2242.
11. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004; 10: 5094-5100.
12. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13: 2151-2157.
13. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005; 11: 2947-2953.
14. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5: 200ra116.
15. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13: 1757-1761.
16. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963; 1: 238-239.
17. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
18. Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat. 2012; 44: 157-165.
19. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513.
20. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-523.
21. Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012; 83: 117-127.
22. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515: 558-562.
23. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515: 568-571.
24. Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6: 5449-5464.
25. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15: 1083-1097.
26. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004; 47: 163-169.
27. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8: 190-198.
28. Ghebeh H, Tulbah A, Mohammed S, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007; 121: 751-758.
29. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373: 123-135.
30. Grosso, J, Horak, CE, Inzunza, D et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Proc Am Soc Clin Oncol. 2013; 31: 3016 (abstr).
31. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20: 5064-5074.
32. Garon, EB, Gandhi, L, Rizvi, N et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol. 2014; 25: LBA43 (abstr).